MSD has announced the approval from the FDA of its combination therapy Recarbrio (imipenem, cilastatin and relebactam) in the treatment of adult patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
The therapy combines the penem antibacterial drug imipenem, the renal dehydropeptidase inhibitor cilastatin sodium, and the beta lactamase inhibitor relebactam.
